Replicor Incis A Canadian Biotechnology Company Focused On The Development Of Its Nucleic Acid Polymernaptechnology For The Treatment Of Hepatitis Bhbvand Deltahdvinfections Naps Are The Only Antiviral Agent To Directly Target The Immunosuppressive Proteinhbsagwhich Drives Chronic Hbv Infection And Liver Disease Our Lead Clinical Nap Drug Product Is Rep 2139 Mga Proprietary Formulation Of Rep 2139 Which Makes Once Weekly Subcutaneous Injections Easily Tolerated Replicor S Latest Clinical Data Demonstrates That Nap Based Combination Therapy Can Restore Immune Control Of Hbv Infection In 78Of Patients And Eliminate Hdv Infection In 74Of Patients These Effects Persist In The Absence Of Any Therapyallowing The Liver To Heal Rep 2139 Mg Based Combination Promises To Revolutionize The Therapy Of Chronic Hbv And Hdv Infection And Play A Pivotal Role In The Who S Goal Of Eliminating Viral Hepatitis By 2030
